RLYB
Rallybio Corp
NASDAQ · Healthcare · Biotechnology · US
$15.90
+0.25%Year over year
Reported trailing growth
- Revenue
- -35.6%
- EBITDA
- +181.8%
- EBIT
- +47.1%
- EPS
- +277.3%
- Free cash flow
- +187.5%
- Operating cash flow
- +187.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +34.9%
- EBITDA
- +53.7%
- EBIT
- +53.6%
- Net income
- +84.5%
- EPS
- +85.1%
- Free cash flow
- +39.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026